News

January 18, 2019January 18, 2019

Sigilon, MIT Collaborating to Develop Programmable Cell Therapies for Hemophilia, Other Diseases

News

Sigilon Therapeutics and the Massachusetts Institute of Technology will work together to develop programmable cell therapeutics for the treatment of hemophilia, lysosomal storage diseases, and other serious chronic illnesses. ... Read more

January 14, 2019January 14, 2019

Researchers Recommend Changes to Protocol in Novoseven/Feiba Combo Therapy

News

Combining the bypassing agents Novoseven and Feiba, with extended time between doses, could be a successful and cost-effective protocol to manage bleeding episodes in hemophilia A patients with inhibitors, according ... Read more

January 11, 2019January 11, 2019

Hepatitis C Virus Is Major Predictor of Liver Cancer in Hemophilia, U.S. Inpatient Data Reveals

News

Past infection with the hepatitis C virus (HCV) is the major risk factor for hepatocellular carcinoma (HCC), the most common type of liver cancer, a large study analyzing more ... Read more

January 9, 2019January 9, 2019

BIVV001 Increases Half-life of Factor VIII in People with Severe Hemophilia A, Phase 1/2a Trial Shows

News

A single dose of BIVV001 significantly increased levels of factor VIII for a week in the blood of people with severe hemophilia A, according to early results of a Phase ... Read more

January 7, 2019January 7, 2019

Novoeight Safe, Effective in Hemophilia A Patients Over Long Term, Phase 3b Trial Shows

News

Long-term treatment with Novoeight (turoctocog alfa) is safe and effective at preventing bleeding episodes in patients with hemophilia A of all ages who had already received prior treatment, a Phase ... Read more

January 4, 2019January 4, 2019

First Hemophilia B Patient Treated with SB-FIX Gene Therapy in Phase 1/2 Trial

News

Sangamo Therapeutics has dosed the first patient in a Phase 1/2 clinical trial testing its investigational genome-editing therapy, SB-FIX, for patients with severe hemophilia B. The Georgetown University and MedStar ... Read more

January 2, 2019January 11, 2019

Catalyst Announces Updates on Two Lead Compounds for Hemophilia

News

Catalyst Biosciences recently announced updates on two of its lead compounds — Factor VIIa (FVIIa) marzeptacog alfa (activated) (MarzAA) and Factor IX (FIX) dalcinonacog alfa (DalcA) — for treatment of hemophilia A or B with inhibitors, and ... Read more

December 21, 2018December 21, 2018

Rising Healthcare Costs Strain EU Budgets Even as New Therapies Flourish

News

Cash-strapped governments across the 28-member European Union are struggling to control runaway healthcare expenditures — at exactly the same time as the promise of new but expensive therapies to ... Read more

December 21, 2018December 21, 2018

Hemophilia Patients Show Worse Oral Hygiene than Healthy Controls, Study Reports

News

Oral hygiene among children and adults with severe hemophilia is poorer than in healthy controls, a single-center study suggests. The study, “Oral hygiene and dentition status in children and ... Read more

December 19, 2018December 19, 2018

Preventive Use of Idelvion Lets Kids with Hemophilia B Need Fewer Infusions, Trial Shows

News

Prophylaxis with Idelvion (rIX‐FP) significantly improved clinical outcomes and quality of life for children with hemophilia B and eased daily life for their caregivers, Phase 3 clinical trial data ... Read more

Pin It on Pinterest